WASHINGTON — President Trump may aggressively negotiate lower drug prices in Medicare using a program that Democrats created and Trump rarely mentions in public.

Since his first term, Trump has demanded that drugmakers charge Americans lower prices for pharmaceuticals, on par with those available in other wealthy countries, a policy often referred to as most-favored nations. He renewed the effort in his current term with an executive order in May, followed by letters to major drugmakers last month demanding those lower prices in Medicare, Medicaid, and the commercial market.

Now, with the latest round of Medicare drug price negotiations underway, some Wall Street analysts and Washington insiders say they think the Trump administration’s Centers for Medicare and Medicaid Services will

See Full Page